Co-amoxiclav levels in bronchial mucosa.

Co-amoxiclav levels in bronchial mucosa.

Effects of Thymol on Co-amoxiclav-Induced Hepatotoxicity in Rats

Background and Aims: Hepatotoxicity induced by Co-amoxiclav has been indicated in multiple studies. Thymol is the main constituent of the Thymus vulgaris essential oil that has antioxidant properties. Even though thymol can exhibit antioxidant activity in vivo models, there is a lack of evidence about the thymol’s effectiveness in drug-induced liver injury. Thus, the present study was conducted...

Co-amoxiclav in recurrent acute otitis media: placebo controlled study.

OBJECTIVE To determine the efficacy of coamoxiclav in children aged 6 months to 12 years with recurrent acute otitis media. DESIGN A randomised double blind placebo controlled clinical trial. SETTING General practice in the Netherlands. PATIENTS 121 children with recurrent acute otitis media, defined by onset of otalgia and otoscopic signs of middle ear infection within four to 52 weeks a...

Co-amoxiclav-induced Stevens Johnson Syndrome in a child

Stevens-Johnson syndrome is an uncommon life threatening disease generally induced by drugs. Antibiotics, mainly sulphonamides, are the most involved drugs in Stevens-Johnson syndrome in children. Co-amoxiclav is a well tolerated antibiotic. It has never been reported to cause, lonely this syndrome in children. Herein, we report a co-amoxiclav-induced Stevens-Johnson syndrome occurring in an 18...

Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens.

BACKGROUND The efficacy of an antibiotic is related to its concentration at the site of infection. Previous studies of the concentrations of amoxycillin and clavulanic acid (co-amoxiclav) in respiratory secretions or whole lung tissue have suffered from methodological problems. The concentration of amoxycillin and clavulanic acid was determined in bronchial mucosal biopsy samples obtained at br...